← BioTransfer GEO Dataset Finder
GEO series

Inhibition of PAK2 in endothelial cells suppresses tumor angiogenesis and promotes immune sensitization through CXCL10

GSE312096 Mus musculus; Homo sapiens Expression profiling by high throughput sequencing 24 samples Submitted 2025/12/10 Platform GPL13112Platform GPL11154
Summary
Tumor angiogenesis is driven by pro-angiogenic factors and results in a disorganized tumor vasculature that limits effective perfusion and immune infiltration. The p21-activated kinase 2 (PAK2) regulates endothelial cell (EC) migration, an essential step of angiogenesis, yet its role in tumor angiogenesis remains ill-defined. Here, we show that endothelial-specific deletion of PAK2 in orthotopic tumor mouse models markedly reduces tumor size and angiogenesis. Loss of endothelial PAK2 also normalizes the remaining tumor vasculature and promotes infiltration of dendritic and NK cells. Mechanistically, PAK2 regulates chemokine expression, notably CXCL10. PAK2 depletion enhances CXCL10 secretion from ECs, and CXCL10 expression is required for the inhibitory effects of PAK2 silencing on EC spouting. Moreover, CXCL10 neutralization in mice reverses the vascular and immune changes induced by endothelial PAK2 deletion. Together, these findings identify endothelial PAK2 as a potential target to limit tumor angiogenesis and reprogram ECs to promote immune infiltration through CXCL10 signaling.
Published in
Inhibition of PAK2 in endothelial cells suppresses tumor angiogenesis and promotes immune sensitization through CXCL10
Corriveau J, Monot P, Delisle C et al. · Cell reports 2026 · PMID 41474619 · doi:10.1016/j.celrep.2025.116840
This dataset
Download

Direct links to NCBI, no account and no request form: the whole study as GSE312096_RAW.tar, processed values as the series matrix, the supplementary file directory, and per-sample supplementary files for any of the 24 samples. Raw sequencing reads are also available from ENA.

Also filed as BioProject PRJNA1372162 and SRA study SRP650328. Searching any of these in the dataset finder brings you back here.

Study design
3 × LLC tumor, CT-PAK2EC, vs 3 × LLC tumor, KO-PAK2EC, vs 3 × HUVEC, siCT, vs 3 × HUVEC, siPAK2,

Supports a between-group comparison across 12 samples.

4 replicated groups read from 24 sample titles; they account for 12 of them. Check it against the sample list below before relying on it.

Samples in this study
Similar datasets

Search all RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.